NCBiotech News

Winston-Salem is adding three healthcare diagnostics companies and a new clinical trials program to its growing regenerative medicine community, marketed as the RegenMed Hub.

Raleigh biopharma company FLAG Therapeutics has achieved a milestone with an FDA Rare Pediatric Disease designation for the company’s investigational treatment for a rare brain tumor in children.

Ag tech pioneers Calyxt and Cibus have entered into a definitive merger agreement under which they will merge in an all-stock transaction.

RTP-based medical device company Asensus says the expansion of machine vision capabilities to its previously cleared Senhance ISU has just received CE Mark, a European Union regulatory approval for medical devices.

Durham pharmaceutical company Eppin Pharma has secured an investment of up to $800,000 from the Male Contraceptive Initiative, a national nonprofit also based in Durham, to help initiate clinical trials for its male birth-control pill.

Oerth Bio, an agricultural biotechnology company in downtown Durham, and Bayer, a global enterprise focused on health care and nutrition, announce a new collaboration and celebrate Oerth’s facilities expansion.

RTP-based Pathalys Pharma has secured $150 million in new financing to support Phase 3 clinical trials for its leading drug candidate to treat end-stage kidney disease.

RTP-based Innatrix is seeking more funding to help it develop its environmentally friendly technology using peptides as a targeted way of controlling agricultural diseases and pests that can devastate crops.

Paris-based Cellectis has successfully dosed its first U.S. patient with its UCART22 allogeneic CAR T-cell therapy product candidate that it made in its new Raleigh facility.

Boone-based MOLTOX gets International Organization for Standardization ISO 9001:2015 certification.

There'll be job info galore at the free public Biomanufacturing and Process Development BioGrow Training and Education Symposium on Thursday, Feb. 9, from 12:30 to 5 p.m. at NCBiotech.

Target RWE, a Durham-based clinical analytics company, has launched 35 new observational disease-state registries to support decision-making in health care.